(Q37950520)

25 August 2017

title

Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis (English)

1 reference

25 August 2017

0 references

2

Kate McKeage

1 reference

25 August 2017

Sean T Duggan

1

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2193-2212

1 reference

https://scigraph.springernature.com/pub.10.2165/11207420-000000000-00000

25 August 2017

exact match

0 references

cites work

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Raloxifene: a review of its use in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Diagnostic criteria for primary osteoporosis: year 2000 revision

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

In vitro metabolism, permeability, and efflux of bazedoxifene in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Safety of long-term bisphosphonate therapy for the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Denosumab: a review of its use in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Chinese women's symptoms: relation to menopause, age and related attitudes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Culture and symptom reporting at menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Vasomotor symptom prevalence and language of menopause in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Uncertain future of trials in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Third-generation SERMs may face uphill battle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Efficacy and safety of bazedoxifene in postmenopausal Asian women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207420-000000000-00000

Endometrial safety: a key hurdle for selective estrogen receptor modulators in development

21 January 2018

1 reference

12 December 2020

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

1 reference

12 December 2020

Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis

1 reference

12 December 2020

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis

1 reference

12 December 2020

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis

1 reference

12 December 2020

Management of osteoporosis in postmenopausal women

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/11207420-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1003421317

0 references

1 reference